Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
China · Delayed Price · Currency is CNY 7.50
+0.08 (1.08%)
Sep 18, 2026, 3:00 PM CST
SHA:600664 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 18,889 | 8,689 | 10,401 | 8,445 | 7,599 | 8,940 | |
Market Cap Growth | 102.16% | -16.46% | 23.17% | 11.14% | -15.00% | 11.79% |
Enterprise Value | 17,589 | 7,944 | 9,834 | 8,373 | 8,608 | 10,444 |
Last Close Price | 7.50 | 3.45 | 4.13 | 3.35 | 3.01 | 3.55 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 37.82 | 24.03 | 16.54 | 21.37 | 16.34 | 24.09 |
Forward PE | 31.25 | 12.32 | 12.48 | 12.48 | 12.48 | 12.48 |
PS Ratio | 1.17 | 0.54 | 0.64 | 0.55 | 0.55 | 0.70 |
PB Ratio | 2.74 | 1.35 | 1.71 | 1.56 | 1.54 | 2.02 |
P/TBV Ratio | 3.35 | 1.66 | 2.12 | 2.00 | 1.98 | 2.69 |
P/FCF Ratio | 52.43 | 30.10 | 15.04 | 9.78 | 14.27 | - |
P/OCF Ratio | 35.33 | 19.76 | 13.13 | 8.89 | 12.22 | - |
PEG Ratio | - | 0.62 | 0.62 | 0.62 | 0.62 | 0.62 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.09 | 0.50 | 0.61 | 0.54 | 0.62 | 0.82 |
EV/EBITDA Ratio | 18.92 | 10.07 | 9.02 | 9.53 | 10.48 | 14.57 |
EV/EBIT Ratio | 26.27 | 13.88 | 11.57 | 13.54 | 15.43 | 23.33 |
EV/FCF Ratio | 48.82 | 27.52 | 14.22 | 9.70 | 16.17 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.19 | 0.19 | 0.29 | 0.34 | 0.44 | 0.52 |
Debt / EBITDA Ratio | 1.41 | 1.48 | 1.55 | 2.01 | 2.48 | 3.06 |
Debt / FCF Ratio | 3.63 | 4.28 | 2.55 | 2.15 | 4.04 | - |
Net Debt / Equity Ratio | -0.30 | -0.34 | -0.31 | -0.22 | -0.06 | 0.16 |
Net Debt / EBITDA Ratio | -2.35 | -2.79 | -1.72 | -1.37 | -0.35 | 1.01 |
Net Debt / FCF Ratio | -5.77 | -7.62 | -2.71 | -1.39 | -0.53 | -3.01 |
Asset Turnover | 1.13 | 1.11 | 1.13 | 1.12 | 1.05 | 1.04 |
Inventory Turnover | 6.23 | 6.00 | 6.11 | 6.14 | 5.40 | 5.01 |
Quick Ratio | 1.19 | 1.12 | 1.08 | 0.99 | 0.93 | 0.82 |
Current Ratio | 1.51 | 1.44 | 1.36 | 1.26 | 1.20 | 1.11 |
Return on Equity (ROE) | 8.22% | 6.35% | 12.00% | 9.15% | 10.94% | 9.75% |
Return on Assets (ROA) | 2.92% | 2.48% | 3.70% | 2.81% | 2.65% | 2.27% |
Return on Invested Capital (ROIC) | 10.54% | 9.40% | 15.90% | 10.15% | 8.31% | 5.82% |
Return on Capital Employed (ROCE) | 9.20% | 8.30% | 13.10% | 10.50% | 10.30% | 9.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.71% | 4.16% | 6.05% | 4.68% | 6.12% | 4.15% |
FCF Yield | 1.91% | 3.32% | 6.65% | 10.22% | 7.01% | -2.67% |
Payout Ratio | 5.72% | 9.21% | 7.49% | 11.17% | 11.68% | 16.59% |
Buyback Yield / Dilution | -1.35% | -2.68% | -1.82% | 4.40% | -4.46% | 1.29% |
Total Shareholder Return | -1.35% | -2.68% | -1.82% | 4.40% | -4.46% | 1.29% |